A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

ABSTRACT: This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

DISEASE(S): Ovarian Cancer,Triple Negative Breast Neoplasms,Gastric Cancer,Colorectal Cancer,Triple Negative Breast Cancer

PROVIDER: 2741380 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR